Saturday, September 27, 2025

Modella AI & AstraZeneca to Speed AI Oncology Development

Related stories

Aisles Launches DREAM: AI-Driven Virtual Reality Evolution

Aisles has unveiled DREAM (Dynamic Reality Experience and Memory),...

TechSee Unveils Visual Remote Assistance with AI (VRAi) on Salesforce

TechSee, a global leader in visual customer assistance, announced...

Rendever and Lenovo Collaborate to Bring Virtual Reality Experiences to Carolina Caring Seniors

Rendever, the Boston-based company pioneering the future of aging...

Ansys 2024 R1 Reimagines the User Experience while Expanding Multiphysics Superiority Boosted by AI

The latest release from Ansys, 2024 R1, introduces an elevated user...

eXeX and Neurosurgeon Dr. Robert Masson Achieve World First Using Apple Vision Pro

eXeX™, a leader in artificial intelligence and mixed reality...
spot_imgspot_img

Modella AI, a leader in artificial intelligence for life sciences, announced a multi-year agreement with AstraZeneca. Under the agreement, Modella AI will provide access to its state-of-the-art multi-modal AI foundation models to AstraZeneca. This agreement aims to harness Modella AI’s advanced foundation models, capable of rich feature extraction from diverse data types, to accelerate clinical development across AstraZeneca’s global oncology portfolio.

“Foundation models are transforming precision medicine. They are the backbone of AI-powered biomedical discovery and mark the first step toward fully autonomous AI agents,” said Jill Stefanelli, CEO of Modella AI. “Our state-of-the-art multimodal foundation models provide powerful features from different data types for downstream tasks. When integrated with AstraZeneca’s research engine, they will have the potential to accelerate data driven development and enable the development of new AI agents that can automate complex R&D workflows.”

Also Read: eClinicalWorks & Sunoh.ai boost documentation, efficiency

AstraZeneca will leverage Modella AI’s platform to enhance its oncology R&D capabilities, with the goal of enhancing clinical development, biomarker discovery, and improving patient outcomes. Both companies will collaborate closely to integrate the models into AstraZeneca’s research pipeline, enabling data-driven discovery at increased scale and speed.

“At AstraZeneca, AI is integrated across every aspect of clinical development,” said Jorge Reis-Filho, Chief AI and Data Scientist, Oncology R&D, AstraZeneca. “Through the use of foundation models, combined with our unique datasets and AI expertise, we are confident in our strategy to accelerate development and increase the probabilities of success in our oncology clinical trials.”

Source: Businesswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img